

REMARKS

Applicants elect with traverse Group II, Claims 2-8, drawn to methods of increasing angiogenesis with traverse. Additionally, Applicants elect species (a) atherosclerosis, coronary heart disease, and arterial occlusive disease with traverse. The claims as drafted clearly define a distinct physiological response and Applicants request the Examiner review the patentability of the claims as drafted. A search of a pharmaceutical composition containing a peptide of SEQ 1 would not place an undue burden upon the Examiner. If the Examiner finds species (a) free of prior art, Applicants request the Examiner review the species (b-d) and any allowable linking claims according to MPEP §809.02(a). Applicants have canceled claims 1 and 3-20 and added claims 21-39. Claims 2 and 21-39 are currently pending. The Applicants respectfully request the Examiner contact them if there are any questions or procedures that need to be addressed.

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. Applicants include herewith payment of Extension fees, thus no additional fees are believed due. If additional fees are due, the Commissioner is authorized to charge additional fees or credit any overpayment to USPTO deposit account # 50-3420, ref. 68004167-001001 (MDB).

Dated: June 20, 2007

Respectfully submitted,

BAKER & MCKENZIE LLP

By /Michael D Berger #52616/

Michael D. Berger Ph.D., Patent Agent
Registration No.: 52,616
Pennzoil Place, South Tower
711 Louisiana, Suite 3400
Houston, Texas 77002-2746 USA
Tel: +1 713 427 5031
Fax: +1 713 427 5099
Attorneys For Applicants